Alivus Life Sciences Limited
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib… Read more
Alivus Life Sciences Limited (ALIVUS) - Net Assets
Latest net assets as of September 2025: ₹30.15 Billion INR
Based on the latest financial reports, Alivus Life Sciences Limited (ALIVUS) has net assets worth ₹30.15 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹36.38 Billion) and total liabilities (₹6.23 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹30.15 Billion |
| % of Total Assets | 82.88% |
| Annual Growth Rate | 39.09% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 70.23 |
Alivus Life Sciences Limited - Net Assets Trend (2021–2025)
This chart illustrates how Alivus Life Sciences Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Alivus Life Sciences Limited (2021–2025)
The table below shows the annual net assets of Alivus Life Sciences Limited from 2021 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹28.17 Billion | +20.80% |
| 2024-03-31 | ₹23.32 Billion | +9.08% |
| 2023-03-31 | ₹21.38 Billion | +4.08% |
| 2022-03-31 | ₹20.54 Billion | +172.91% |
| 2021-03-31 | ₹7.53 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Alivus Life Sciences Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 136.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹17.77 Billion | 63.08% |
| Common Stock | ₹245.07 Million | 0.87% |
| Other Comprehensive Income | ₹99.69 Million | 0.35% |
| Other Components | ₹10.06 Billion | 35.70% |
| Total Equity | ₹28.17 Billion | 100.00% |
Alivus Life Sciences Limited Competitors by Market Cap
The table below lists competitors of Alivus Life Sciences Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gempharmatech Co. Ltd. A
SHG:688046
|
$333.19 Million |
|
Revance Therapeutics, Inc.
NASDAQ:RVNC
|
$333.19 Million |
|
AXTRART_AXTRA FUTURE CITY
BK:AXTRART
|
$333.28 Million |
|
Blend Labs Inc
NYSE:BLND
|
$333.30 Million |
|
Amorepacific Group
KO:002795
|
$333.07 Million |
|
Betagro Public Company Limited
F:J74
|
$333.04 Million |
|
Alligo AB Series B
ST:ALLIGO-B
|
$332.94 Million |
|
Hangzhou Huaxing Chuangye Communication Technology Co Ltd
SHE:300025
|
$332.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alivus Life Sciences Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 23,323,220,000 to 28,173,720,000, a change of 4,850,500,000 (20.8%).
- Net income of 4,856,270,000 contributed positively to equity growth.
- New share issuances of 6,690,000 increased equity.
- Other comprehensive income increased equity by 99,690,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹4.86 Billion | +17.24% |
| Share Issuances | ₹6.69 Million | +0.02% |
| Other Comprehensive Income | ₹99.69 Million | +0.35% |
| Other Changes | ₹-112.15 Million | -0.4% |
| Total Change | ₹- | 20.80% |
Book Value vs Market Value Analysis
This analysis compares Alivus Life Sciences Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.08x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 15.24x to 4.08x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-03-31 | ₹61.44 | ₹936.10 | x |
| 2022-03-31 | ₹167.66 | ₹936.10 | x |
| 2023-03-31 | ₹174.51 | ₹936.10 | x |
| 2024-03-31 | ₹190.35 | ₹936.10 | x |
| 2025-03-31 | ₹229.27 | ₹936.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alivus Life Sciences Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 17.24%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 20.47%
- • Asset Turnover: 0.70x
- • Equity Multiplier: 1.21x
- Recent ROE (17.24%) is below the historical average (25.27%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 46.71% | 18.89% | 0.93x | 2.65x | ₹2.76 Billion |
| 2022 | 20.38% | 20.06% | 0.84x | 1.20x | ₹2.13 Billion |
| 2023 | 21.84% | 22.80% | 0.76x | 1.26x | ₹2.53 Billion |
| 2024 | 20.19% | 21.55% | 0.77x | 1.22x | ₹2.38 Billion |
| 2025 | 17.24% | 20.47% | 0.70x | 1.21x | ₹2.04 Billion |
Industry Comparison
This section compares Alivus Life Sciences Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $10,697,551,025
- Average return on equity (ROE) among peers: 14.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alivus Life Sciences Limited (ALIVUS) | ₹30.15 Billion | 46.71% | 0.21x | $333.13 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |